This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Aspirin in reduction of risk of thromboembolism

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Aspirin has an irreversible inhibition of platelet cyclo-oxygenase that lasts until the cell is degraded.

A few weeks of antiplatelet therapy prior to surgery reduces the risk of deep vein thrombosis (DVT) and pulmonary embolus (PE) by approximately 50% (1).

The risk of DVT and PE in patients that are chronically immobilised with medical conditions is also reduced by antiplatelet therapy.

  • short-term aspirin therapy can lower the risk for venous thromboembolism (VTE) in high-risk patients (2)

Antiplatelet therapy should be continued upon discharge from hospital whilst the patients remains at risk of thromboembolism and in the absence of contraindications to taking aspirin.

Trial evidence revealed that low-dose aspirin treatment has little effect on the prevention of VTE in initially healthy women.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.